title: First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
abstract: OBJECTIVE
  To identify the maximum-tolerated dose (MTD) and pharmacokinetics of oral perifosine.
  
  
  METHODS
  Patients with solid tumours received perifosine at dosages ranging from 100-800mg/week. Eligibility criteria included life expectancy>12weeks, WHO performance status2, normal blood, liver and renal functions and no recent anticancer treatment. Drug concentrations were analysed by HPLC-MS/MS.
  
  
  RESULTS
  Thirty six patients were recruited (75% males, mean age 54.7years, performance status 1 in 72.2%). Adverse events included nausea (69.4%), diarrhoea (55.6%), vomiting (52.8%) and abdominal pain (13.9%). Antiemetic regimens including glucocorticoids, dopamine antagonists and 5-HT3-antagonists were used as treatment and/or prophylaxis in 50% of the patients. Though MTD was formally not reached with 800mg/week, the treatment discontinuation due to diarrhoea and vomiting likely related to perifosine in two cases led to the decision to stop further dose escalation. Pharmacokinetics after a single dose were median t(max)=8.0-24.2h, median t(1/2)=81.0-115.9h and mean(geo) CL/f=0.28-0.43mL/min/kg. Urinary excretion was below 1%. Perifosine slightly accumulated and steady state was nearly reached after 2-3weeks.
  
  
  CONCLUSIONS
  Oral perifosine was tolerable up to 600mg/week in cancer patients when administered with meal and prophylactic antiemetics. Based on its half-life of about 4days, a weekly regimen may be appropriate.
authors.affiliation: Klinik für Tumorbiologie an der Albert-Ludwigs Universität, Freiburg, Germany. unger@tumorbio.uni-freiburg.de
authors.forename: Clemens
authors.initials: C
authors.lastname: Unger
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Berdel
authors.forename: Axel-R
authors.initials: AR
authors.lastname: Hanauske
authors.forename: Herbert
authors.initials: H
authors.lastname: Sindermann
authors.forename: Jürgen
authors.initials: J
authors.lastname: Engel
authors.forename: Klaus
authors.initials: K
authors.lastname: Mross
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000284:Administration, Oral; D000932:Antiemetics / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D010767:Phosphorylcholine; C105905:perifosine